Recombinant Human EPO-Fc Protein

Product Discontinued

Recombinant Human EPO-Fc Protein Summary

• Description: A biologically active dimeric, glycosylated, polypeptide chain consisting of two mature human EPO molecules linked to the Fc portion of human IgG1 and corresponding to EPO
  
  

  Source: CHO cell line

  
  
  A biologically active dimeric, glycosylated, polypeptide chain consisting of two mature human EPO molecules linked to the Fc portion of human IgG1 and corresponding to EPO

  Source: CHO cell line

• Preparation Method: Source: CHO Recombinant Human EPO/Fc produced in CHO is a dimeric, glycosylated, polypeptide chain consisting of two mature human EPO molecules linked to the Fc portion of human IgG1. The Fc component contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. As a result of glycosylation, the recombinant protein migrates with an apparent molecular mass of 140 kDa in non-reducing SDS-PAGE. Lyophilized from a 0.2um filtered concentrated solution in PBS, pH 7.4.
• Details of Functionality: Fully biologically active when compared to standard. The ED50 determined by a cell proliferation assay using human megakaryoblastic leukemia cells is less than 2 ng/ml, corresponding to a specific activity of > 5.0 x 10^5 IU/mg.
• Source: CHO
• Protein/Peptide Type: Recombinant Protein
• Gene: EPO
• Purity: > 98 % pure by SDS-PAGE and HPLC
• Endotoxin Note: Less than 1EU/ug of endotoxin as determined by LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Functional
  • SDS-Page
• Theoretical MW: 140 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.4.
• Concentration: LYOPH
• Purity: > 98 % pure by SDS-PAGE and HPLC
• Reconstitution Instructions: Reconstitute with sterilized distilled water or 0.1% BSA aqueous buffer to a final concentration of 0.1 - 1.0 mg/ml.

Background

Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients. Erythropoietin/Fc Chimera is a long-acting version of EPO.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: EPO